Trials / Terminated
TerminatedNCT01083641
Estrogen for Triple Negative Breast Cancer
A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- University of Wisconsin, Madison · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of Estradiol treatment for advanced breast cancer that is hormone receptor negative and Her2/neu negative. The study will also use tumor tissue from your original diagnosis or from a biopsy you may have had for your cancer to look at hormone receptors in the lab. The tissue left over from your previous surgery or a previous biopsy will be used for research tests to check whether a different estrogen receptor (estrogen receptor beta) is seen in the tumor and if that makes estrogen work better.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Estradiol | 10mg oral three times daily |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2013-06-01
- Completion
- 2015-03-01
- First posted
- 2010-03-10
- Last updated
- 2019-12-09
- Results posted
- 2017-03-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01083641. Inclusion in this directory is not an endorsement.